Chemoproteomic technologies can mine chemically-accessible amino acids via intrinsic reactivity toward electrophilic probes. However these approaches cannot discern which reactive residues contribute to protein function and therefore prioritize for drug discovery. 

In this webinar:

• Development of CRISPR-based Oligo Recombineering (CORe) to systematically prioritize reactive amino acids according to their contribution to protein function.
• How CORe couples protein sequence and function with biological fitness, outperforming traditional genetic workflow efficiency by orders-of-magnitude.
• Results including discovery of reactive cysteines decorating the ribosome of apicomplexan parasite Toxoplasma gondii that were found to be critical for parasite growth, with target-based screening validating apicomplexan translation machinery as a novel target for covalent ligand development.